Signature Cord Prime™ Receives Investigational New Drug (IND) Approval from FDA for Phase 1 Study in Patients with Symptomatic Osteoarthritis of the Knee
Dallas, Texas., Feb. 16, 2021 /PRNewswire/-– Signature Biologics, LLC., a regenerative medicine company focused on the development, manufacture, and commercialization of cellular and tissue based products (HCT/P’s) for unmet human medical needs, today announced that the U.S. Food and Drug Administration (FDA) has approved an IND Application to proceed with the study of Signature Cord [...]
